New therapies for conditions ranging from diabetes and adrenal insufficiency to ovarian cancer and multiple myeloma and a biosimilar version of Roche’s Herceptin could this week receive a recommendation for marketing across the EU.
At its final meeting of the year, the European Medicines Agency’s key scientific committee, the CHMP, is – among many...








